Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity in terms of patient populations and underlying biological mechanisms.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.

Four tips for midsized companies when entering new global markets.

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease compared to other glucose-lowering drugs.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Introducing a new series highlighting ways pharma companies can up their game in winning earned media—and ultimately deliver greater impact and value from their messaging.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in hospitalized infants under six months of age with respiratory syncytial virus.

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer advertising amid policy and government agency overhauls in the US.

The campaign also has a specific focus on Black Americans, who are more likely to develop the disease.

The campaign is launching alongside positive news for the company’s Phase 3 trials for a GBS treatment.

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared to standard-of-care chemotherapy.

The formula for future-proofing pharmaceutical networks to withstand any disruption.

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy Questionnaire – Clinical Summary Scores and peak oxygen consumption.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses results from new data on the role of T cell dysfunction in post-acute infection syndromes.

Marketing and sales personnel who leverage the expertise and insights of MedAffairs can often have better success.

Despite meeting key pharmacokinetic goals, a potential case of drug-induced liver injury led Pfizer to conclude that danuglipron’s risk-benefit profile did not support further development for chronic weight management.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explains how Juvena plans to differentiate JUV-112 from other obesity therapeutics targeting adipose tissue.

Addressing key challenges in the modern sales sector requires a fundamental shift in training strategies.

Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research sectors to address the financial and structural barriers that impede rare disease drug development.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated significantly improved overall survival and overall response rate in patients with unresectable or metastatic hepatocellular carcinoma.

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical and electronics industries.